Matthew Sydes
Overview
Explore the profile of Matthew Sydes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
396
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mintz H, Dosanjh A, Parsons H, Sydes M, Bryan R, James N, et al.
BMJ Oncol
. 2025 Jan;
2(1):e000038.
PMID: 39886499
No abstract available.
2.
McCarthy M, Gillies K, Rousseau N, Wade J, Gamble C, Toomey E, et al.
HRB Open Res
. 2023 Jul;
6:10.
PMID: 37456658
: Data sharing enables researchers to conduct novel research with previously collected datasets, thus maximising scientific findings and cost effectiveness, and reducing research waste. The value of sharing, even de-identified,...
3.
Turco F, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, et al.
Eur Urol
. 2022 Apr;
82(1):e18-e19.
PMID: 35440417
No abstract available.
4.
Turco F, Armstrong A, Attard G, Beer T, Beltran H, Bjartell A, et al.
Eur Urol
. 2022 Apr;
82(1):6-11.
PMID: 35393158
Patients with advanced prostate cancer (APC) may be at greater risk for severe illness, hospitalisation, or death from coronavirus disease 2019 (COVID-19) due to male gender, older age, potential immunosuppressive...
5.
Houghton C, McCarthy M, Gillies K, Rousseau N, Wade J, Gamble C, et al.
HRB Open Res
. 2021 Jul;
4:47.
PMID: 34124575
: Data sharing enables researchers to conduct novel research with previously collected data sets, thus maximising scientific findings and cost effectiveness, and reducing research waste. The value of sharing anonymised...
6.
Reddy D, Shah T, Dudderidge T, McCracken S, Arya M, Dobbs C, et al.
Contemp Clin Trials
. 2020 Apr;
93:105999.
PMID: 32302790
Introduction: Focal therapy (FT) targets individual areas of cancer within the prostate, providing oncological control with minimal side-effects. Early evidence demonstrates encouraging short-medium-term outcomes. With no randomized controlled trials (RCT)...
7.
Embleton-Thirsk A, Deane E, Townsend S, Farrelly L, Popoola B, Parker J, et al.
Clin Trials
. 2019 Jul;
16(5):502-511.
PMID: 31347385
Background: The ICON6 trial (ISRCTN68510403) is a phase III academic-led, international, randomized, three-arm, double-blind, placebo-controlled trial of the addition of cediranib to chemotherapy in recurrent ovarian cancer. It investigated the...
8.
Griffiths G, Cowan R, Grigor K, Uscinska B, Sydes M, Russell M
PLoS One
. 2019 Jan;
14(1):e0210785.
PMID: 30650143
Background: Pure squamous cell carcinoma (SCC) of the urinary tract is rare in the UK and has a poor prognosis compared with transitional cell carcinoma (TCC). Cisplatin based chemotherapy has...
9.
Gilbert D, Duong T, Sydes M, Bara A, Clarke N, Abel P, et al.
BJU Int
. 2018 Feb;
121(5):680-683.
PMID: 29388336
No abstract available.
10.
Vale C, Fisher D, Tierney J, White I, Sydes M, Carpenter J
Eur Urol
. 2017 Dec;
73(3):e49-e50.
PMID: 29233663
No abstract available.